Fortunately, the expression levels of PDCD1 (PD-1), CD274 (PD-L1), and CTLA4, the vital immune checkpoints in glioma, were significantly higher in IS2 than other subtypes, which indicated that patients receiving ICIs therapies might achieve a better curative effect [44]. The gene discussed is CD274; the disease is glioma.